Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. by Lin, Cheng-Te Major et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Pathology Faculty Publications Pathology
1-1-2016
Human herpesvirus multiplex ddPCR detection in
brain tissue from low- and high-grade astrocytoma
cases and controls.
Cheng-Te Major Lin
Emily C. Leibovitch
George Washington University
M. Isabel Almira-Suarez
George Washington University
Steven Jacobson
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_path_facpubs
Part of the Medical Pathology Commons, Pathology Commons, and the Virology Commons
This Journal Article is brought to you for free and open access by the Pathology at Health Sciences Research Commons. It has been accepted for
inclusion in Pathology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
APA Citation
Lin, C., Leibovitch, E. C., Almira-Suarez, M. I., & Jacobson, S. (2016). Human herpesvirus multiplex ddPCR detection in brain tissue
from low- and high-grade astrocytoma cases and controls.. Infectious Agents and Cancer, 11 (). http://dx.doi.org/10.1186/
s13027-016-0081-x
RESEARCH ARTICLE Open Access
Human herpesvirus multiplex ddPCR
detection in brain tissue from low- and
high-grade astrocytoma cases and controls
Cheng-Te Major Lin1,2, Emily C. Leibovitch1,2, M. Isabel Almira-Suarez2 and Steven Jacobson1*
Abstract
Background: Glioblastoma (GBM) is a fatal CNS malignancy, representing 50 % of all gliomas with approximately
12–18 months survival time after initial diagnosis. Recently, the human herpesvirus cytomegalovirus (CMV) has been
suggested to have an oncogenic role, yet this association remains controversial. In addition, human herpesvirus 6
(HHV-6) and Epstein-Barr virus (EBV) have also been associated with low-grade gliomas, but few studies have
examined HHV-6 and EBV in glioblastomas. Droplet digital PCR (ddPCR) is a highly precise diagnostic tool that
enables the absolute quantification of target DNA. This study examines the association between multiple human
herpesviruses and astrocytomas.
Methods: This study analyzed 112 brain tissue specimens, including 45 glioblastoma, 12 astrocytoma grade III, 2
astrocytoma grade II, 4 astrocytoma grade I, and 49 controls. All brain tissue samples were de-identified and
pathologically confirmed. Each tissue block was sectioned for DNA extraction and CMV, EBV, HHV-6A and HHV-6B,
and a cellular housekeeping gene were amplified by ddPCR.
Results: Neither CMV nor HHV-6A were detected in any of the astrocytoma samples. However, HHV-6B (p = 0.147)
and EBV (p = 0.049) had a higher positivity frequency in the GBM compared to the controls.
Conclusion: The undetectable CMV DNA in the astrocytoma cohort does not support the observation of an increased
prevalence of CMV DNA in GBM, as reported in other studies. EBV has a significantly higher positivity in the GBM
cohort compared to the controls, while HHV-6B has a higher but not statistically significant positivity in the case cohort.
Whether these viruses play an oncogenic role in GBM remains to be further investigated.
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Background
Gliomas are brain tumors that develop from glial cells.
Approximately a quarter of diagnosed gliomas are astro-
cytomas, which are scaled from grade I to grade IV
based on histological features [1]. According to the
World Health Organization (WHO) classification for
CNS tumors: astrocytoma grade I and astrocytoma grade
II are classified as low-grade astrocytomas, while astro-
cytoma grade III and astrocytoma grade IV are classified
as high-grade astrocytomas. Furthermore, astrocytoma
grade IV is also referred to as glioblastoma (GBM).
Patients with GBM have a median survival of 12 months
and an average 5-years survival rate less than 5 % [2, 3].
Although GBM has been extensively studied in clinical
and laboratory settings, there are limited effective treat-
ments for this malignant tumor [4].
The herpersviruses are large, enveloped, double-
stranded DNA viruses. Currently, there are more than
100 known herpesviruses, and nine human herpesviruses
(HHVs) that can cause a wide range of diseases. The β-
herpesvirus subfamily, one of three herpesvirus subfam-
ilies, has been suggested to be associated with central
nervous system (CNS) impairments and diseases, such
as hearing loss, CNS inflammation, and primary brain
tumors. Recently, accumulating evidence indicates that
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cytomegalovirus (CMV), a β-herpesvirus, is associated
with GBM, but these reports remain controversial [5, 6].
For example, some studies have demonstrated CMV
viral genome expression in glioblastoma samples
compared to other types of non-neurological disease
patients, whereas other have found no trace of CMV
DNA in glioblastoma. The discrepancy between these
findings may be contributed by differences in the experi-
mental methodology, brain tissue specimen preservation,
and DNA detection methods [7]. The vast majority of
studies were done by PCR or immunohistochemistry,
which focused on the molecular identification of viral
DNA or viral proteins, respectively. Such discrepancy
encourages a more in-depth investigation of the role of
CMV and its association with glioblastoma.
Another human β-herpesvirus, human herpesvirus 6
(HHV-6) has also been associated with low-grade
gliomas [8–10], but few studies have examined HHV-6
in glioblastomas. There are two species of HHV-6,
HHV-6A and HHV-6B. Both viruses differ in their epi-
demiological, biological, and molecular properties. Less
is known about the specificity of HHV-6A-associated
diseases compared with HHV-6B, which is the etiologic
agent of roseola, and associated with CNS diseases such
as status epilepticus, mesial temporal sclerosis, and
multiple sclerosis [11–13]. Another subfamily of human
herpesviruses, the γ-herpesviruses, establishes latent
infection in B-lymphocytes and may cause these cells to
proliferate abnormally, leading to Kaposi’s sarcoma and
CNS lymphoma [14]. Epstein-Barr virus (EBV) is
thought to be associated with specific oncogenic condi-
tions, such as Hodgkin’s lymphoma, Burkitt’s lymphoma,
nasopharyngeal carcinoma and a subset of gastric
carcinomas [15]. EBV genomic DNA has also been de-
tected in high-grade glioma samples by unmapped next-
generation sequencing, but mechanisms of pathogenesis
are still unclear [16]. Overall, the extent to which human
herpesviruses are associated with GBM is currently
unknown.
More recently, a randomized and blinded clinical trial
examined the effectiveness of a CMV vaccine (CMV
pp65 RNA pulsed DCs) with different pre-conditioning
regimens for treating GBM. Aside from identifying
an immunogenic preconditioning regimen, the study
demonstrated that an increase in CMV pp65-specific
immune responses correlated with overall GBM survival
[17]. Although these clinical trials have shown promis-
ing results regarding positive clinical outcomes for
GBM patients, the significance of CMV in GBM re-
mains controversial [18]. However, this study provides
clinical evidence that anti-viral therapies can improve
patient outcomes, which suggests that viruses, specific-
ally herpesviruses, might play a role in these malignant
brain tumors.
To investigate the presence of herpesvirus genome
sequences in different grades of astrocytomas and
controls, we utilized a novel methodology to detect and
quantify multiple human herpesviruses. Droplet digital
PCR (ddPCR) is a newly developed technology that
divides PCR reactions into tens of thousands droplets
and detects the amplification in each droplet, which
enables us to detect and quantify target DNA directly
[19, 20]. Other studies have used this highly precise
technology to detect bacterial or viral genomic DNA
sequences in various types of samples [21–23]. To quan-
tify multiple human herpesviruses in astrocytoma brain
tissue specimens and non-neurological disease control
specimens, we developed a multiplexing method, which
enables the simultaneous screening of multiple target
sequences in brain tissue samples.
This study quantitated CMV, HHV-6A, HHV-6B and
EBV viral DNA in astrocytoma (WHO grade I-IV) and
non-neurological disease control tissues with a newly
developed ddPCR multiplexing method.
Methods
Study design
This was a retrospective and health center-based study.
The study screened for multiple human herpesviruses
(CMV, HHV-6A, HHV-6B, and EBV) in different grades
of astrocytomas and non-neurological disease controls,
which excluded other brain cancers and other CNS
diseases.
Samples were obtained from the George Washington
University Hospital and the National Institutes of
Health, and the protocol was approved by both institu-
tional review boards. The study collected specimens
preserved by three different methods: formalin-fixed
paraffin embedded (FFPE), optimal-cutting temperature
(OCT), and fresh frozen. Study brain tissue specimens
were selected based on medical records from the institu-
tions. A total of 112 unique adult brain tissue samples
were included in the study. The study collected astrocy-
tomas (WHO grades I-IV) and non-neurological disease
controls. The astrocytoma FFPE cases were comprised
of four grade I, one grade II, two grade III, and 19 grade
IV (GBM). Also, there were ten grade III astrocyto-
mas and 20 grade IV (GBM) collected as the OCT bio-
preserved tissue. Lastly, there was a total of six fresh
frozen astrocytomas grade IV (GBM) and one fresh fro-
zen astrocytoma grade II. Non-neurological disease tis-
sue specimens were selected based on medical records
from both institutes. These controls were obtained from
autopsy tissue specimens, which were not associated
with neurological disease as cause of death. There were
49 non-neurological disease brain specimens, comprised
of 32 fresh frozen samples and 17 FFPE-preserved sam-
ples (Table 1). The fresh frozen control samples were
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Table 1 Age, sex, cause of death for non-neurological disease controls (n = 49)
Age (years) Sex Cause of death
Fresh Frozen Tissue
33 M Coronary Artery Thrombosis
34 F Asthma
64 M ASCVDa
50 M ASCVD
34 M Abdominal Injuries
48 M HASCVDb
64 F ASCVD
43 F HASCVD
30 M Multiple Injuries
34 M HASCVD
40 F Multiple Injuries
43 F HASCVD
52 M ASCVD
49 M Pulmonary Thromboembolism
59 M Bronchopneumonia
40 F Pulmonary Embolism
28 M ARVCc
53 M HASCVD
44 M HASCVD
50 F HASCVD
35 F Streptococcal Sepsis
48 F HASCVD
37 M ASCVD
63 F Acute Myocardial Infarction
23 M Hypertrophic Cardiomyopathy
56 F Asthma
27 M ASCVD
57 M ASCVD
54 F ASCVD
63 M HASCVD
36 M ASCVD
60 F HASCVD
FFPE-Preserved Tissue
74 F Breast Cancer
64 M Lipoid Pneumonia
56 M Ascending Aortic Dissection
43 M Acute Pneumonia
64 F Acute Ischemic Bowel Disease
63 F Congestive Heart Failure
65 M Laryngeal Squamous Cell Carcinoma
86 M Acute Abdominal Compartment Syndrome
41 M P. aeruginosa Sepsis
68 F Acute Fibrinous and Organizing Pneumonia
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from the cerebellum and parietal regions of the brain,
whereas the FFPE-preserved control samples were from
the left fronto-parietal cortex. The adult control cohort
had an average age of 51.7 years old with 20 females and
29 males. The astrocytoma (WHO grades I–IV) tissue
specimens had an average age of 35 years old. After the
genomic DNA extraction, the samples were screened
by ddPCR for multiple human herpesviruses based on
highly conserved genomic sequences. Cases classified by
different astrocytoma WHO grades were compared with
the non-neurological disease controls with regard to hu-
man herpesviruses positivity frequency and viral loads.
Brain tissue DNA extraction
Formalin-Fixed Paraffin Embedded (FFPE)
FFPE brain tissue genomic DNA was extracted using the
QIAamp DNA FFPE Tissue kit (Qiagen, Valencia, CA).
A total of 500 μm (ten sections 50 μm thick) of FFPE tis-
sue was used in the genomic DNA extraction, which was
performed according to the manufacturer’s specifica-
tions. Samples were eluted with 100 μl of buffer AE.
Optimal-Cutting Temperature (OCT)
OCT brain tissue genomic DNA was extracted using the
QIAamp DNA Mini kit (Qiagen, Valencia, CA). A total
of 500 μm (ten sections 50 μm thick) of OCT tissue was
used in the genomic DNA extraction. The OCT
compound was dissolved in 1 ml of PBS (Ca-Mg free)
and spun at 8000 rpm for 5 min. PBS washes were re-
peated if the samples had significant remaining amounts
of OCT. Samples were eluted with 100 μl of buffer AE.
Fresh frozen
Fresh frozen brain tissue genomic DNA was extracted
by the DNeasy Blood and Tissue kit (Qiagen, Valencia,
CA). A total of 25 mg of fresh frozen brain tissue was
used in the genomic DNA extraction, performed accord-
ing to the manufacturer’s instructions. Samples were
eluted with 100 μl of buffer AE.
Multiplex digital droplet PCR assay
The CMV, EBV, and HHV-6 primers were selected from
highly conserved regions, ul55, lmp1, and u57, respect-
ively (Table 2) [24–27]. Different probes were used to
distinguish between HHV-6A (FAM) and HHV-6B
(VIC), as described by Leibovitch et al. in 2014 [25]. The
20X ddPCR primer/probe solution was composed of
18 μl of 100 μM forward primer, 18 μl of 100 μM reverse
primer, 5 μl of 100 μM probe (FAM or VIC), and 79.5 μl
PCR quality distilled water. With the multiplexing
method, the 10X ddPCR primer/probe solution was
composed of 9 μl of 100 μM forward primer, 9 μl of
100 μM reverse primer, 2.5 μl of 100 μM probe (FAM or
VIC), and 59 μl PCR quality distilled water. The ddPCR
primer/probe concentration difference generated distinct
populations on the Y-axis. HHV-6A, HHV-6B, and
rpp30 were detected with the 20X ddPCR mastermix so-
lution; meanwhile, CMV and EBV were detected with
the 10X ddPCR mastermix solution. Each plot displayed
the viruses or the housekeeping gene (rpp30) popula-
tions in a brain tissue specimen. rpp30 (NCBI gene
10556) is an housekeeping gene, which was used as a
human genome reference loci, and served as an indica-
tor of brain tissue DNA quality and cellular quantity. A
specimen was considered positive when the 2-D fluores-
cence plots showed at least two dots at the expected
amplitude. Each multiplex positive sample was further
confirmed by a singleplex ddPCR assay, which targeted
only one genomic sequence per axis. Samples were con-
sidered positive only if both multiplex and singleplex as-
says showed equal or more than two droplets at the
expected amplitude. More detailed multiplex ddPCR
method is provided by the Bio-Rad ddPCR guidelines
[20]. The viral load calculation and statistical analysis
were based on the multiplex ddPCR assay.
Statistical analysis
With the retrospective study design, we computed the
positivity frequency proportions in cases and controls to
examine the proportional differences between each hu-
man herpesvirus and different grades of astrocytoma or
Table 1 Age, sex, cause of death for non-neurological disease controls (n = 49) (Continued)
67 M Acute Myocardial Infarction
55 M Subacute Bacterial Endocarditis
66 M Mallory Weiss Tear
84 F Sudden Cardiac Death
49 F Sickle Cell Disease
65 F Acute Myocardial Infarction
70 M Congestive Heart Failure
a Atherosclerotic Cardiovascular Disease
b Hypertensive Arteriosclerotic Cardiovascular Disease
c Arrhythmogenic right ventricular cardiomyopathy
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controls. p-value at 95 % confidence level is presented in
each group. Based on the Fisher’s Exact test, we included
the p-value to determine statistically significant propor-
tions between cases and controls. We used RStudio soft-
ware 0.99.486 version developed by RStudio, Inc. and
Prism 6 developed by GraphPad software, Inc to analyze
the data.
Results
ddPCR multiplex assay characterization
The present study optimized the CMV ddPCR assay by
comparing three published CMV primers and probe sets
[24, 28, 29]. After adjusting the published sequences to
fit ddPCR parameters, one primer/probe set had a high
GC content that impeded efficient amplification of target
sequences [29]. Therefore, two CMV primer/probe sets
were compared for sensitivity and performance in the
ddPCR assay (Fig. 1a and c). Though both detected
CMV positivity in the positive control, one set generated
a tighter, higher amplitude positive population (Fig. 1a),
suggesting greater target DNA affinity compared to the
other CMV primer/probe set, which generated a more
scattered positive population (Fig. 1c). Therefore, the
ddPCR-adapted CMV primer/probe set shown in Fig. 1a
was used for this study and multiplexed with HHV6A,
HHV6B, and EBV. The HHV-6A and HHV-6B primer/
probe sets were described in a recent study of coinfec-
tion [25]. The EBV primer/probe set was adapted from
published sequences [27] and optimized to fit ddPCR-
specific parameters (unpublished data). The results in
Fig. 1c and d are representative of these combinations.
Clear separations can be seen with HHV-6A and CMV
on the FAM channel (Y-axis) and HHV-6B on the VIC
channel (X-axis) (Fig. 1b). Likewise, distinct populations
are seen with EBV on the FAM channel (Y-axis) and
RPP30 on the VIC channel (X-axis) (Fig. 1d). These data
show that successful herpesvirus multiplex ddPCR can be
achieved, with detection sensitivities that are comparable to
singleplex ddPCR (data not shown) [24, 25].
Undetectable CMV viral genome sequences in GBM
Each astrocytoma case was screened for CMV by both
the multiplex and singleplex ddPCR assays. All clinical
tissue specimens were collected either as FFPE, OCT, or
fresh frozen biopreservation methods. Within each
astrocytoma case cohort and non-neurological disease
control cohort, there was no frequency difference in
CMV detection by ddPCR assay between these preserva-
tions methods. Furthermore, no CMV reactivity was
observed in any tissue specimens when assayed by either
a singleplex or multiplex ddPCR. As shown in Table 3,
the present study did not detect CMV genomic DNA in
any astrocytoma case (n = 63) with either ddPCR assay,
although one FFPE non-neurological disease tissue spe-
cimen showed CMV positivity with a viral load of 9023
copies/106 cells (Fig. 2). Collectively, the absence of
CMV DNA in our GBM cohort does not support an
association of CMV and glioblastoma.
High HHV-6B positivity frequency in astrocytomas
By contrast with CMV, HHV-6B was detected at a rela-
tively high frequency in the brain tissue specimens com-
pared to the other human herpesviruses investigated in
this study (HHV-6A, CMV, and EBV). Figure 2 shows
HHV-6B, EBV and CMV viral loads in each brain tissue
specimen. HHV-6B was the most frequently detected
virus among the brain specimens, with viral loads ran-
ging from less than 100 to greater than 20,000 copies
per million cells. HHV-6B was detected in 3/19 (15.8 %)
FFPE GBM samples, 3/20 (15 %) OCT GBM samples, 2/
10 (20 %) OCT astrocytoma grade III, and 2/32 (6.2 %)
fresh frozen control samples (Table 3). However, HHV-
6B was also detected in a low number of brain tissues
from non-neurological disease controls (2/49, 4.1 %),
Table 2 ddPCR assay primers and probes
Forward primer (5′-3′) Reverse primer (5′-3′) Probe
HHV-6A u57 CCGTGGGATCGTCTAAAATTATAGATGT CCACACTAGTCCGGACGGATAA FAM –
CTGGAACTGTATAATAGG
– MGBNFQ
HHV-6B u57 CCGTGGGATCGTCTAAAATTATAGATGT CCACACTAGTCCGGACGGATAA VIC –
CTGGAGCTGTACAACAG
– MGBNFQ
CMV ul55 TGGGCGAGGACAACGAA TGAGGCTGGGAAGCTGACAT FAM –
TGGGCAACCACCGCACTGAGG
– 3BHQ
EBV lmp1 AAGGTCAAAGAACAAGGCCAAG GCATCGGAGTCGGTGG FAM –
AGCGTGTCCCCGTGGAGG
– MGBNFQ
RPP30a GATTTGGACCTGCGAGCG GCGGCTGTCTCCACAAGT VIC –
CTGACCTGAAGGCTCT
– MGBNFQ
a Ribonuclease P protein subunit p30
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and was therefore not statistically significant in the
GBM cohort (p = 0.147). HHV-6B was also detected in
2/10 (20 %) astrocytoma grade III samples, but again the
proportion compared to controls was not statistically
significant (p = 0.170) (Fig. 3). HHV-6A was not detected
in any of the astrocytoma or non-neurological disease
tissue specimens. HHV-6 is a ubiquitous human herpes-
virus in the adult population and the CNS has been sug-
gested as a site of viral latency and reactivation, which is
consistent with the HHV-6B positivity observed in our
non-neurological disease control cohort [30].
Significantly higher proportion of EBV in GBM
While high levels of HHV6B could be demonstrated in
high-grade astrocytoma cases (grade III and IV), EBV
was only detected in the FFPE GBM samples, 4/19
(21.1 %) and not in any controls (Fig. 3 and Table 3)
(p = 0.049). These samples had EBV viral loads ran-
ging from less than 1000 to greater than 17,000 cop-
ies per million cells (Fig. 2). Most cases did not show
co-infection (two or more viruses) by the multiplex
ddPCR assay, however two FFPE GBM tumor speci-
mens were positive for both HHV-6B and EBV. Both
cases were verified by both multiplex and singleplex
assays. Collectively, the results in this study demon-
strated that HHV-6B and EBV, but not CMV, could
be amplified from high-grade astrocytomas using a
human herpesvirus multiplex ddPCR.
Discussion
In recent years, many studies of herpesviruses and brain
tumors have examined the association between CMV
Fig. 1 Characterization of the HHV-6A, HHV-6B, CMV, EBV and RPP30 multiplex ddPCR assays. A CMV plasmid was used as a positive control to
evaluate each CMV primer/probe set, with results shown in (a and b). a The ddPCR-adapted CMV (20X) primer/probe set used in this study [24] is
shown on the FAM channel; c A second ddPCR-adapted CMV (20X) primer/probe set [28] that was evaluated but not used in this study is shown
on the FAM channel; b HHV-6A and HHV-6B infected cells were used as positive controls in this multiplex characterization. HHV-6A (20X) and
CMV (10X) are on the FAM channel and HHV-6B (20X) is on the VIC channel. Droplets containing multiple DNA targets are double positive for
FAM and VIC (shown in the upper right quadrant); d An EBV transformed lymphoblastoid cell line was used as a positive control in this multiplex
characterization. EBV is shown on the FAM channel and the housekeeping gene RPP30 is shown on the VIC channel
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and high-grade astrocytomas, but the relationship is still
controversial [31]. Also, no previous study has systemat-
ically examined CMV, HHV-6A, HHV-6B, and EBV viral
DNA in low- and high-grade astrocytomas. The human
herpesviruses have the ability to become latent in
specific host cell types, primarily in the CNS and lymph-
oid tissue [32]. A review of recent studies that used im-
munohistochemistry (IHC), in situ hybridization (ISH),
and PCR to detect CMV in GBM tumor specimens
showed that results vary from undetected to 100 % posi-
tivity [18]. IHC and PCR each focus on different molecu-
lar targets, so detection selectivity discrepancies might
be contributing to discordant results. Both techniques
have their respective advantages and disadvantages. For
instance, the interpretation of IHC is complicated due to
background pigments, such as hematoidin, hemosiderin,
formalin precipitates, and unspecific staining [5]. While
PCR only focuses on a selected genomic sequence, off
target amplification may result in false positives, and
negative PCR results, i.e. the non-amplification of a spe-
cific amplicon, cannot be interpreted as the absence of
the viral genome.
The absence of CMV in the GBM samples in this
present study does not support a CMV genomic DNA
and glioblastoma association, in contrast to other studies
that have reported a high prevalence of CMV genomic
Table 3 Positivity frequency of four human herpesviruses across all brain specimens
CMV HHV-6A HHV-6B EBV
FFPE-Preserved Tissue
Astrocytoma Grade IV (n = 19) 0/19 0/19 3/19 (15.8 %) 4/19 (21.1 %)
Astrocytoma Grade III (n = 2) 0/2 0/2 0/2 0/2
Astrocytoma Grade II (n = 1) 0/1 0/1 0/1 0/1
Astrocytoma Grade I (n = 4) 0/4 0/4 0/4 0/4
Control (n = 17) 1/17 (5.9 %) 0/17 0/17 0/17
OCT-Preserved Tissue
Astrocytoma Grade IV (n = 20) 0/20 0/20 3/20 (15 %) 0/20
Astrocytoma Grade III (n = 10) 0/10 0/10 2/10 (20 %) 0/10
Fresh Frozen Tissue
Astrocytoma Grade IV (n = 6) 0/6 0/6 0/6 0/6
Astrocytoma Grade II (n = 1) 0/1 0/1 0/1 0/1
Control (n = 32) 0/32 0/32 2/32 (6.2 %) 0/32
Fig. 2 Viral loads of HHV-6B, EBV and CMV in PCR positive high-
grade astrocytoma cases and controls. Viral loads are expressed
as viral copies per million cells, and stratified by tissue type
(cases or controls) and preservation method. Only positive results
are shown. Blue circles correspond to HHV-6B positive samples,
red squares correspond to EBV positive samples, and orange
diamonds correspond to CMV positive samples. FFPE – formalin
fixed paraffin embedded; OCT – optimal cutting temperature;
Ast. III – Astrocytoma Grade III; GBM – Glioblastoma
Fig. 3 Positivity frequency of HHV-6B, EBV and CMV across
high-grade astrocytoma cases and controls. Percent frequency of
detected HHV-6B, EBV, and CMV across all biopreservation
methods, stratified by tumor grade (GBM and astrocytoma grade
III) compared to non-neurological disease controls. Statistical
significance is defined as p < 0.05 C.I 95 % (n.s – not significant).
FFPE – formalin fixed paraffin embedded; OCT – optimal cutting
temperature; Ast. III – Astrocytoma Grade III; GBM – Glioblastoma
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DNA in glioblastoma by PCR [33–35]. Most studies have
utilized either a protein or a genomic sequence targeting
technique, but not both, to detect CMV. A few studies
have proposed that certain onco-viruses might trigger
viral DNA recombinogenic activities, which could pro-
mote oncogenesis with the secondary loss of the viral
genome in tumor cells [36, 37]. Viruses that initiate such
“hit and run oncogenesis” in the host may be absent at
the time of screening.
Other than screening for known viral sequences or
using viral-specific IHC assays, a less biased approach
would be to sequence brain tumors and search for
viral or non-human nucleic acid sequences, for
example using a next-generation sequencing platform
[38]. With this approach, a report in 2014 demon-
strated EBV and HHV-6 viral sequences in 5/21
(24 %) and 1/21 (5 %) of GBM cases, respectively
[16]. These viral positivity levels are consistent with
the results of this present study, which detected EBV
and HHV-6B in 4/45 (8.9 %) and 6/45 (13.3 %) of
GBM cases, respectively. However, since the 2014
study did not investigate a control cohort, this limited
the interpretation of the roles of EBV and HHV-6 in
their GBM cohort.
Although to our knowledge no studies have specifically
investigated HHV-6B in glioblastoma, some studies have
suggested the involvement of HHV-6 in patients with
gliomas. A 2012 study reported 17 of 40 (42.5 %) glioma
samples with detectable HHV-6, compared to one of 13
(7.7 %) controls, using nested-PCR [8]. Furthermore,
among the glioma cohort, 7/14 GBM (50 %) were HHV-
6 positive. In a separate 2009 study, Crawford and col-
leagues reported a three-fold increase in HHV-6 positiv-
ity by IHC in glial tumors compared to non-glial tumors
in an adult cohort, and 14/30 (46.7 %) of CNS tumors
were HHV-6 positive by nested-PCR compared to 0/25
control brains [39]. While these data suggest the in-
volvement of HHV-6 in at least a subset of brain
tumors, the specific potential oncogenic mechanisms of
HHV-6 are not fully understood.
We found EBV to be present at a significantly higher
frequency in GBM compared to controls. EBV is an
oncovirus that is responsible for the development of
Hodgkin’s lymphoma, nasopharyngeal carcinoma and
Burkitt’s lymphoma. However, few studies have exam-
ined the relationship between EBV and astrocytomas,
specifically. In a study by Neves et al. in 2012, EBV was
the most frequently detected human herpesviruses in
pilocytic astrocytoma (WHO grade I) by PCR, but at
fairly low levels (<100/100 ng cellular DNA) [40]. Neves
and colleagues detected only one sample with CMV, but
did not detect any HHV-6. Further epidemiological and
molecular studies are needed to investigate the role of
EBV in astrocytomas.
Among the glioblastoma cohort in this present study,
there were two cases with co-infection of EBV and
HHV-6B. Currently, no study has reported EBV and
HHV-6 co-infection in glioblastoma, though this has
been observed in suspected viral CNS disease samples
[41, 42]. Several in-vitro studies indicate that HHV-6
may activate EBV expression, which might promote
EBV-associated diseases later in life [43, 44]. A 2015
study reported two encephalitis cases with HHV-6 and
EBV co-infection detected by PCR [45]. However, the
coinfection of these two herpesviruses in our case cohort
cannot be seen as causal agents of the astrocytoma. The
detection of HHV-6B and EBV could be a mere conse-
quence of molecular events within the tumor that may
be associated with reactivation of latent virus [46].
In our cohort, the sensitivity of multiple human
herpesvirus detection did not vary with the biopreserva-
tion method. All preservation methods were comparable
in terms of virus detection, though fresh-frozen remains
the most ideal for viral detection. Some studies have
raised concerns about the possibility of DNA degrad-
ation upon long-term storage in FFPE. The vast majority
of studies used FFPE-preserved tissues for the detection
of viral protein or DNA. However, in a study that exam-
ined the quality of FFPE extracted DNA, no significant
differences were found between DNA extracted from
FFPE tissue blocks that had been stored for less than
one year and FFPE tissue blocks that had been stored for
1–11 years [47].
Lastly, the ddPCR multiplex assay is a highly
precise viral diagnostic tool that enables the absolute
quantification of multiple viral target regions [48, 49].
Although multiplex qPCR has a shorter analysis time,
high sensitivity, and a broad dynamic range, the
multiplex ddPCR assay has lower variability, outstand-
ing accuracy, and provides better quality of quantifi-
cation in the multiplex assay [49]. A study reported
by Hayden in 2013 compared quantitative real-time
PCR (qRT-PCR) and ddPCR for the detection of
CMV in clinical samples, and reported that ddPCR
showed less variability when detecting samples at
higher concentrations [50]. Overall, the study indi-
cated that ddPCR is an accurate assay for detecting
CMV viral loads in clinical samples. In our study, we
compared a multiplex ddPCR assay with a singleplex
ddPCR assay, and there was no significant difference
in quantification or qualification ability. However, any
type of PCR system is prone to the misclassification
of viral detection due to low sensitivity or specificity
of the primer/probe set. As a result, optimization of
the primers and probe becomes critical. Regardless of
the PCR type, a multiplex assay can be adopted as a
diagnostic tool that quantifies multiple viral targets,
while conserving samples in a clinical setting.
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Conclusion
Despite the availability of advanced genomic technology,
establishing an association between ubiquitous viruses
and primary brain tumors remains challenging. Once
again, the present study is a cross-sectional screening of
multiple herpesviruses in low- and high-grade astrocy-
toma specimens. Other detection methods and study de-
signs should be used before making firm conclusions
about the association of CMV with glioblastoma.
However, these results have shown that several other
herpesviruses may be associated with high-grade astro-
cytomas. Moreover, HHV-6 and EBV need to be further
investigated in other types of primary brain cancers and
their possible mechanisms of pathogenesis further ex-
plored. Ultimately, blinded and randomized clinical trials
of anti-viral agents or other anti-viral intervention strat-
egies may be the only way to describe an association be-
tween human herpesviruses and GBM or other cancers.
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